Allworth Financial’s Fate Therapeutics FATE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$23.4K Buy
8,676
+5,424
+167% +$10K ﹤0.01% 3071
2026
Q1
$3.9K Buy
3,252
+2,828
+667% +$3.44K ﹤0.01% 4093
2025
Q4
$417 Sell
424
-494
-54% -$593 ﹤0.01% 4566
2025
Q3
$1.16K Buy
918
+914
+22,850% +$985 ﹤0.01% 4208
2025
Q2
$5 Hold
4
– – ﹤0.01% 4570
2025
Q1
$6 Hold
4
– – ﹤0.01% 4032
2024
Q4
$6 Sell
4
-37
-90% -$93 ﹤0.01% 3919
2024
Q3
$144 Buy
41
+37
+925% +$144 ﹤0.01% 3637
2024
Q2
$18 Hold
4
– – ﹤0.01% 3649
2024
Q1
$30 Hold
4
– – ﹤0.01% 3546
2023
Q4
$15 Hold
4
– – ﹤0.01% 3404
2023
Q3
$9 Sell
4
-143
-97% -$474 ﹤0.01% 3404
2023
Q2
$700 Buy
147
+90
+158% +$497 ﹤0.01% 2826
2023
Q1
$325 Buy
+57
New +$344 ﹤0.01% 2923
2022
Q4
– Sell
-30
Closed -$1K – 3066
2022
Q3
$1K Buy
30
+17
+131% +$491 ﹤0.01% 2367
2022
Q2
$0 Buy
13
+7
+117% +$193 ﹤0.01% 2514
2022
Q1
$0 Buy
+6
New +$232 ﹤0.01% 2191
2021
Q4
– Sell
-156
Closed -$9K – 1990
2021
Q3
$9K Buy
+156
New +$12.2K ﹤0.01% 1370

Other funds holding FATE

Allworth Financial's FATE Position: Q2 2026 in Review

Allworth Financial increased its Fate Therapeutics (FATE) stake by 167% in Q2 2026, buying an estimated $10K and bringing the position to 8,676 shares worth $23.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3071.

Allworth Financial first reported a position in FATE in Q3 2021 and has held it in 18 quarters since. 156 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Allworth Financial held 8,676 shares of Fate Therapeutics worth $23.4K as of Q2 2026.
  • Allworth Financial bought 5,424 Fate Therapeutics shares in Q2 2026, an estimated $10K.
  • Fate Therapeutics made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #3071 holding.
  • Allworth Financial first reported a position in Fate Therapeutics in Q3 2021 and has held it in 18 quarters since.
  • 156 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.